Statson Pharmaceuticals Establishes New Brand, KC Specialty Therapeutics, In Kansas City, Kansas
11/08/2013
KC Specialty Therapeutics LLC will locate alongside Statson’s Animal Health at the Bioscience & Technology Business Center located on the University of Kansas Medical Center campus. Over the next year, the company will create job opportunities in Kansas City and continue to grow its presence over time.
"Stason Pharmaceuticals has been very impressed with the biosciences opportunities in the Kansas City region since moving Stason Animal Health's national headquarters here earlier this year," said Diana Wood, Vice President of corporate development for Stason Pharmaceuticals and CEO for KC Specialty Therapeutics LLC. "The KC Animal Health Corridor and broader life sciences community have been incredibly supportive."
Today's announcement comes just 90 days after Stason Pharmaceutical's animal division, Stason Animal Health, announced it was relocating its corporate headquarters to the KC Animal Health Corridor.
"We are thrilled that Stason Pharmaceuticals values our region's strong biosciences business environment," said Bob Marcusse, President and CEO, Kansas City Area Development Council. "We look forward to seeing both Stason Pharmaceuticals and KC Specialty Therapeutics grow in our region."
Project Announcements
Japan-Based TOCALO Plans Chandler, Arizona, Operations
04/17/2026
Dakota Bodies Expands Liberty, Missouri, Operations
04/17/2026
Linde Plans Garysburg, North Carolina, Air Separation Operations
04/17/2026
Netherlands-Based Signature Foods USA Plans Easley, South Carolina, Manufacturing Operations
04/16/2026
Lumber Liquidators Plans Lawrenceburg, Tennessee, Headquarters Operations
04/16/2026
Canada-Based Bioriginal Food & Science Plans Grand Junction, Colorado, Operations
04/15/2026
Most Read
-
Economic Developer Role Shifting from Deal-Making to Systems Stewardship
Q1 2026
-
What Companies Need from Modern Manufacturing Sites
Q1 2026
-
Top States for Doing Business in 2024: A Continued Legacy of Excellence
Q3 2024
-
Capitalizing on the OBBBA Before the 2026 Cliff
Q1 2026
-
Last Word: Don’t Lose by Winning
Q1 2026
-
Advanced Manufacturing Isn’t a Buzzword—It’s a Different Location Strategy
Q1 2026
-
40th Annual Corporate and 22nd Annual Consultant Site Selection Survey Results
Q1 2026